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Supplemental Materials and Methods 
 
1. Protein expression and purification  
 
Proteins were cloned and expressed using standard molecular biology and 
biochemical techniques. Crp TE was cloned and expressed as previously described.1,2 
CrpD-M2 gene was amplified by PCR with a forward primer with a restriction site of 
BamHI (CAAGGATCCTTACGTACTACTAATAGCGCA) and a reverse primer with a 
restriction site of XhoI (ATGCTCGAGTAGTTGTTGAATTGGTACTAATGG). The 
amplicons were purified and digested for cloning into pET28a.  The plasmid encoding N-
terminal His6-CrpD-M2 was transformed into E. coli BAP1 and grown at 37 °C in TB 
medium to an OD600 of ~0.8 in 2 L flasks. The cultures were cooled to 18 °C, and 
isopropyl β-D-thiogalactopyranoside was added to a final concentration of 0.2 mM and 
grown for additional 12-16 h with shaking. The cells were harvested by centrifugation 
and frozen at -20 °C. Cell pellets were thawed to 4 °C and resuspended in 5X volume of 
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lysis buffer (20 mM HEPES, pH 7.8, 300 mM NaCl, 20 mM imidazole, 1 mM MgCl2, 
0.7 mM Tris(2-carboxyethyl) phosphine (TCEP), ~100 mg CelLytic Express (Thermo, 
Rockfield, IL) before lysis via sonication. Centrifugation at 25,000 x g for 60 min 
provided clarified lysates. Proteins were purified using Ni-Sepharose affinity 
chromatography with a gravity column. Briefly, after filtration of the supernatant through 
a 0.45 μm membrane, the solution was loaded onto a 5 mL HisTrap nickel-nitrilotriacetic 
acid column. The column was washed with 10 column volumes of buffer A (20 mM 
HEPES, pH 7.8, 300 mM NaCl, 20 mM imidazole, 1 mM TCEP, 10% glycerol), 10 
column volumes of buffer B (20 mM HEPES, pH 7.8, 300 mM NaCl, 50 mM imidazole, 
1 mM TCEP, 10% glycerol), and then eluted with buffer C (20 mM HEPES, pH 7.8, 300 
mM NaCl, 400 mM imidazole, 1 mM TCEP, 10% glycerol). Protein containing fractions 
were pooled and desalted with pre-equilibrated PD-10 gravity flow columns in storage 
buffer (20 mM HEPES, pH 7.4, 150 mM NaCl, 1 mM TCEP, 10% glycerol). Fractions 
were combined, concentrated, frozen, and stored at -80 °C. Purity estimate of 80% was 
based on SDS-PAGE (Figure S2). 
 
2. Analysis of purified CrpD-M2 by FTICR-MS 
CrpD-M2 integrity was determined by peptide map fingerprinting. Briefly, CrpD-
M2 was reduced (10 mM DTT, 50 oC 30 min) and digested with trypsin (TPCK 
modified, Thermo, Rockfield, IL).  The sample was desalted with Handee Microspin 
columns (Thermo, Rockfield, IL) packed with 20 μL of 300 Å polymeric C4 resin 
(Grace-Vydac, Deerfield, IL). Samples were loaded onto the columns and washed with 
30 column volumes of 0.1% formic acid prior to elution with 10 column volumes of 50% 
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acetonitrile plus 0.1% formic acid.  Peptides were then introduced into the FTICR-MS 
(described below) at a rate of 70 µL/hour with direct infusion.  Peaks were identified with 
the THRASH algorithm as implemented in MIDAS data analysis workstation (National 
High Magnetic Field Laboratory, Tallahassee, FL).  Peaks were matched against a 
theoretical digest of CrpD-M2 (Protein Prospector, UCSF, San Francisco, CA) with a 
tolerance of ±20 ppm. Note that the low sequence coverage observed is not surprising 
due to lack of LC separation, however, sequence coverage is obtained from residue 3-
1,922 out of 1,964 suggesting that the purified protein is full-length (Figure S3). 
Identified peptides are presented in Table S1. 
 
3. ATP-[32P] PPi exchange assay 
The exchange assay for determining A domain substrate specificity was 
conducted using modified protocol.3 All acid substrates used in the assay were purchased 
from Sigma (St. Louis, MO). The reaction mixture (100 µL) contained 75 mM Tris-Cl, 
pH 7.5, 10 mM Mg Cl2, 5 mM TCEP, 5 mM ATP, 1 mM tetrasodium pyrophosphate 
(PPi), 5 mM free acid substrate, and 0.5 µCi tetrasodium [32P] PPi (Perkin Elmer, Boston, 
MA). The ATP-PPi exchange was initiated by adding 1 µM of CrpD-M2 and allowed to 
proceed for 10 minutes at room temperature. The reaction was then terminated by the 
addition of cold charcoal solution (500 µL, 1.6% w/v activated charcoal, 0.1 M 
tetrasodium pyrophosphate, and 5% perchloric acid in water). Free [32P]-PPi was 
removed by centrifugation of the sample, and washing the charcoal pellet twice with 
wash buffer (0.1 M tetrasodium pyrophosphate, and 5% perchloric acid in water). The 
charcoal was finally resuspended in water (500 µL) and the bound radioactivity was 
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determined by scintillation counting on a Beckman LS6500 (Fullerton, CA). All 
experiments were carried out in duplicate for each substrate with a negative control 
without enzyme.  
 
4. Biochemical reactions and LC FTICR-MS2 analysis 
 
Enzymatic reaction conditions were as follows: 100 mM Tris-Cl, pH 7.5, 10 mM 
MgCl2, 5 mM ATP, 1 mM TCEP, 500 µM free-acid extender unit, 100 µM SNAC-ABC 
chain elongation intermediate, 1 mM NADH, 1 mM NADPH, 1 µM CrpD-M2, and 1 µM 
Crp TE. Reaction components were excluded as appropriate (eg. no enzyme for no 
enzyme control reactions, no chain elongation intermediate for PPi adenylation domain 
assays). 
For T-domain active site loading experiments samples were incubated for 60 
minutes at room temperature. Reactions were raised to pH 8 by the addition of 
concentrated Tris-base, after 4X dilution in 100 mM ammonium bicarbonate.  Trypsin 
(TPCK-modified, Thermo, Rockfield, IL) at 1 mg/mL was added to a molar ratio of 10:1 
(CrpD-M2:trypsin). Samples were incubated at 37 °C for 15 minutes, prior to addition of 
10% formic acid to pH 4.  Reactions were stored at -80 °C until analysis. The CrpD-M2 
T domain active site (QLVEIFQEVLNLPSIGIHDNFFSLGGHSLLAVR) was first 
identified by accurate mass using LC FTICR-MS (Figure S3B). After the tryptic 
peptide's retention time (80-81 minutes) and the most abundant charge state (4+, 1001.5 
m/z) were identified, online MS2 was performed using external quadruple isolation and 
IRMPD1,2 in the FTICR cell for ion activation. The phosphopantetheine ejection ions 
specific markers for the post-translational modification were observed at 261.1 m/z (Ppt1) 
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and 359.1 m/z (Ppt2).1,2 In addition, the apo T-domain, charge-reduced, parent containing 
the residual phosphate (+80) or dehydroalanine (-18) was also observed. A short 
sequence of b-ions was observed, and added to the confirmation of peptide identity. 
Identified parent and product ions are shown in Table S2, and the parent ion mass 
spectrum is shown in Figure S3B. 
 Liquid chromatography of trypsin digested CrpD-M2 was performed on an 
Agilent 1100 with a Jupiter C18 300 Å 1 x 150 mm column (Phenomenex, Torrence, CA) 
at a rate of 75 µL/min using a column heater at 50 °C.  Twenty µL of sample was injected 
followed by an LC gradient: 2% solvent B 0-20 min, to 60% solvent B at 90 min, to 98% 
solvent B 105'-108', back to 2% B at 110', and equilibrated at 2% B for 10 minutes. 
Mobile phase A was water with 0.1% formic acid, and mobile phase B consisted of 
acetonitrile with 0.1% formic acid. 
FTICR-MS (APEX-Q with Apollo II ion source and actively shielded 7 T magnet; 
Bruker Daltonics, Ballerica, MA) was conducted in positive ion mode from m/z 200–
2,000. Electrospray was conducted at 3,000-4,000 V 16-30 scan per spectra utilizing 1 s 
external ion accumulation in the hexapole prior to analysis in the FTICR using a loop 
value of 4 for direct inject samples.  For online LC FTICR-MS external ion accumulation 
time was set to 0.33 s with 1 scan per spectra and 128 K signal detected. Collision cell 
pressure was kept at 5.8e-6 torr and either CID or IRMPD was utilized for MS2.  LC-
FTICR MS data was processed in Data Analysis (Bruker Daltonics, Ballerica, MA) and 
using DECON2LS and VIPER (Pacific Northwest National Labs, Richland, WA) for 
online THRASH analysis. Protein Prospector (UCSF, San Francisco, CA) was used to 
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assist with manual assignment of MSn data.  All experiments were performed at least 
twice to verify the findings.   
 
5. Determination of CrpD-M2 active site loading 
The CrpD-M2 T domain active site peptide as identified above, was then loaded 
with the substrates: L-2HIC, D-2HIC, AKGB, and 2-KIC.  Peaks were initially identified 
through LC FITCR-MS using accurate mass. For online confirmation of peak identity the 
same LC gradient (described above) was run using a Thermo LTQ linear ion trap (LIT) 
MS.  Product peaks were subjected to MS2 (phosphopantetheine ejection assay) and MS3 
(apo T-domain, charge-reduced, parent containing the residual dehydroalanine (-18) as 
precursor) for further confirmation.1,2 Notably, the phosphopantetheine ejection assay 
performed well on the low resolution instrument, as previously reported.4 See Table S4 
for LC FTICR-MS and Table S5 for LC LIT-MS results. The loading and reaction of 
substrates on the CrpD-M2 T domain was monitored by looking for mass shifts to the 
loaded T-domain peptide by LC FITCR-MS.  Identified peaks were verified by online 
MS2 and MS3 experiments using a LIT-MS.   
Linear ion trap mass spectrometry was performed using an LTQ (Thermo, 
Rockfield, IL).  A number of data independent scans were defined for each sample 
including: a survey scan, MS2 fragmentation of the target T-domain peptide in the 3+ and 
4+ charge state, and MS3 of the charge reduced Apo - 18 products from the MS2 scans.  
An isolation window of 4 m/z was utilized, with normalized collision energy of 40%.  
Xcaliber (Thermo, Rockfield, IL) was used for initial data processing, followed by 
Protein Prospector (UCSF, San Francisco, CA) for fragmentation assignments. 
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6. Cryptophycin MS and MS2 
 
 The cryptophycin products were generated by reacting CrpD-M2, SNAC-ABC 
chain elongation intermediates, unit D extender units, ATP, and Crp TE together as 
described above. After 60 minutes, the proteins were removed by precipitation with 3 
volumes of methanol, pelleted by centrifugation, and the reactions were injected into the 
LC FTICR-MS (described above). Online MS2 CID spectra were assigned to 
cryptophycin 3 and 51 (Figure S6). Product spectra were interpreted manually using 
cryptophycin 3 as a standard based on coelution with an authentic standard (Figure S7). 
Cyclic peptide product ion assignment was aided by tools developed in the Dorrestein 
and Pevzner laboratories.5,6 Cryptophycin MS2 CID fragmentation spectra were assigned 
with the assumption that fragmentation would occur across the most labile bonds in the 
gas phase—amide and ester linkages.5,6  This characteristic breaks cryptophycin into the 
A, B, C, and D unit constituents with associated water (+/- 18), ammonia (- 17) and CO (- 
28) based mass shifts. Two key spectral features are present: the +14 Da shift of the CD + 
H2O, ABC - 18, and MH+ ions between cryptophycin 3 (Figure S6A) and 51 (Figure 
S6B),—corresponding exactly to the one methyl group difference due to the different unit 
C moieties. This diagnostic feature helps to validate both spectral assignments. 
 
7. Cryptophycin 3 authentic standard elution 
 
 An authentic standard of cryptophycin 3 was used to verify the identity of 
chemoenzymatically generated cryptophycin 3 by HPLC co-elution analysis. A 
SHIMADZU LCMS-2010EV system (Columbia, MD) was used for HPLC separation 
with a detection wavelength of 218 nm. The product separation was carried out with a 
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Waters XBridge C18 (3.5 µm, 2.1 × 150 mm) column (Milford, MA) at a flow rate of 200 
µL/min. Solvent B (acetonitrile with 0.1% formic acid) gradually increased from 50% to 
99% and solvent A was water with 0.1% formic acid. 
 
8. Synthesis of SNAC-ABC cryptophycin elongation intermediates (Scheme 1). 
 
Scheme 1. Synthesis of SNAC-ABC cryptophycin elongation intermediates. 
 
Materials and Methods. Unless otherwise stated, all reactions were performed 
with no extra precautions taken to exclude moisture or air. Boc-β-Ala-OH was purchased 
from Advanced ChemTech (Lousville, KY), (R)-3-(Boc-amino)-2-methylpropionic acid 
was purchased from Sigma (St. Louis, MO), and Boc-3-amino-2,2-dimethyl-propionic 
acid was purchased from PolyPeptide (San Diego, CA). Solvents were purchased as ACS 
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Grade (CH2Cl2, DMF, and MeOH) from Sigma (St. Louis, MO) or Thermo (Rockfield, 
IL) and used as received. N-acetylcysteamine (SNAC), 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDC), 4-dimethylaminopyridine (DMAP), 
triethylamine (TEA), benzotriazole-1-yl-oxy-tris-pyrrolidino-phosphonium 
hexafluorophosphate (PyBOP), trifluoroacetic acid (TFA), and all other chemicals were 
obtained from Sigma (St. Louis, MO) or Advanced ChemTech (Lousville, KY) and used 
directly.  
1H and 13C NMR spectra were recorded on a Varian 500 MHz or a Varian 
Performa IV 600 MHz instrument. Proton chemical shifts are reported in ppm referenced 
to the centerline of CDCl3 (7.26 ppm) or CD3OD (3.31 ppm) as the internal standard, 
carbon chemical shifts are reported in ppm referenced to the centerline of CDCl3 (77.16 
ppm) or CD3OD (49.00 ppm) as the internal standard. Proton chemical data are described 
as follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, m 
= multiplet, b = broad), coupling constant (in Hz), and integration. High-resolution mass 
spectra were obtained on an Agilent Accurate-Mass Q-TOF 6520 (Santa Clara, CA). 
Semi-preparative HPLC was performed with a Beckman Coulter System Gold 126 HPLC 
(Brea, CA) utilizing a Waters Prep C18 column (Milford, CA). Analytical thin-layer 
chromatography (TLC) was performed on silica gel 60 F254 TLC glass plates with a 
fluorescent indicator from EMD Chemicals (Gibbstown, NJ). EMD Silica Gel 60 
Geduran® (particle size 0.040 – 0.063 mm, Gibbstown, NJ) silica gel was used for flash 
chromatography. Visualization was accomplished by UV fluorescence quenching (254 
nm) and by p-anisaldehyde or potassium permanganate staining. 
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Experimental Procedures 
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(R)-S-2-acetamidoethyl 3-((R)-3-(3-chloro-4-methoxyphenyl)-2-
((2E,5S,6R,7E)-5-hydroxy-6-methyl-8-phenylocta-2,7-dienamido)propanamido)-2-
methylpropanethioate (3). A solution of compound 28 (27 mg, 0.053 mmol) in CH2Cl2 
(500 μL) was treated with trifluoroacetic acid (250 μL) and stirred at room temperature 
for 1 hour. Volatiles were then removed under vacuum and residue dissolved in DMF (1 
mL). To this solution was added a solution of 30 (10 mg, 0.041 mmol), PyBOP (32 mg, 
0.061 mmol), triethylamine (12 μL, 0.081 mmol), and DMAP (1 mg, 0.008 mmol). 
Reaction stirred for 18 hours at room temperature and then diluted with CH2Cl2 (5 mL). 
Organic layer washed with saturated aqueous NH4Cl (5 mL), brine (5 mL), and water (5 
mL), then dried with Na2SO4. Solvent removed under vacuum, residue dissolved in 
MeOH, and purified by HPLC (XBridge C18 Prep Column, 5 µm, 10 x 250 mm, 3 
mL/min, 50:50 to 90:10 MeOH/H2O over 25 minutes, Rt = 21.1 minutes). Fractions 
containing the desired compound were concentrated in vacuo and dried by lyophilization 
to recover 4.2 mg of pure 3 as a white solid (13%). 1H NMR (CD3OD, 600 MHz) δ 7.36 
(d, J = 7.3 Hz, 2H), 7.27 (m, 3H), 7.18 (m, 1H), 7.13 (dd, J = 2.2, 8.4 Hz, 1H), 6.96 (d, J 
= 8.4 Hz, 1H), 6.80 (m, 1H), 6.40 (d, J = 15.9 Hz, 1H), 6.24 (dd, J = 8.5, 16.0 Hz, 1H), 
6.00 (d, J = 15.4 Hz, 1H), 4.57 (t, J = 8.2 Hz, 1H), 3.83 (s, 3H), 3.64 (m, 1H), 3.41 (m, 
1H), 3.33 (m, 1H), 3.16 (m, 1H), 2.99 (m, 4H), 2.82 (m, 2H), 2.36 (m, 4H), 1.91 (s, 3H), 
1.15 (d, J = 6.8 Hz, 3H), 1.02 (d, J = 4.6 Hz, 3H) ppm; 13C NMR (CD3OD, 150 MHz) δ 
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202.87, 173.55, 173.47, 170.30, 168.12, 155.39, 143.51, 139.07, 132.55, 132.09, 131.88, 
131.58, 129.47, 128.04, 127.13, 126.10, 123.23, 121.75, 113.39, 75.35, 56.59, 56.16, 
44.24, 43.28, 39.98, 38.79, 37.95, 29.31, 22.58, 17.49, 15.69 ppm; HRMS (ESI+) m/z 
666.2386 [M + Na]+ (C33H42ClN3NaO6S requires 666.2381). 
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(R)-S-2-acetamidoethyl-3-((R)-3-(3-chloro-4-methoxyphenyl)-2-
((2E,5S,6R,7E)-5-hydroxy-6-methyl-8-phenylocta-2,7-dienamido)propanamido)-2-
methylpropanethioate (4) and S-2-acetamidoethyl 3-((R)-3-(3-chloro-4-
methoxyphenyl)-2-((2E,5S,6R,7E)-5-hydroxy-6-methyl-8-phenylocta-2,7-
dienamido)propanamido)-2,2-dimethylpropanethioate (5) were prepared in a manner 
analogous to that used to prepare compound 3 and purified by HPLC. Compound 4: 12%; 
Rt = 20.5 minutes; 1H NMR (CD3OD, 600 MHz) δ 7.36 (d, J = 7.8 Hz, 2H), 7.25 (m, 
3H), 7.17 (dd, J = 7.1, 7.4 Hz, 1H), 7.11 (dd, J = 2.0, 8.4 Hz, 1H), 6.96 (d, J = 8.5 Hz, 
1H), 6.80 (m, 1H), 6.41 (d, J = 16.0 Hz, 1H), 6.23 (dd, J = 8.5, 16.0 Hz, 1H), 5.99 (d, J = 
15.4 Hz, 1H), 4.55 (t, J = 6.0 Hz, 1H), 3.83 (s, 3H), 3.65 (m, 1H), 3.43 (m, 4H), 2.99 (m, 
4H), 2.83 (dd, J = 8.5, 13.8 Hz, 1H), 2.70 (m, 2H), 2.39 (m, 2H), 2.32 (m, 1H), 1.91 (s, 
3H), 1.15 (d, J = 6.0 Hz, 3H) ppm; 13C NMR (CD3OD, 150 MHz) δ 198.43, 173.46, 
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173.41, 170.29, 168.14, 155.38, 143.53, 139.07, 132.55, 132.09, 131.86, 131.55, 129.47, 
128.04, 127.13, 126.08, 123.21, 121.75, 113.36, 75.35, 56.58, 56.12, 44.24, 44.06, 40.00, 
38.80, 37.96, 36.53, 29.37, 22.55, 17.50 ppm; HRMS (ESI+) m/z 652.2226 [M + Na]+ 
(C32H40ClN3NaO6S requires 652.2224).  
Compound 5: 8%; Rt = 21.5 minutes; 1H NMR (CD3OD, 600 MHz) δ 7.37 (m, 2H), 7.28 
(m, 3H), 7.16 (m, 2H), 6.98 (d, J = 8.7 Hz, 1H), 6.81, (m, 1H), 6.42 (d, J = 15.8 Hz, 1H), 
6.24 (dd, J = 8.3, 15.9 Hz, 1H), 6.01 (d, J = 15.2 Hz, 1H), 4.64 (m, 1H), 3.85 (s, 3H), 
3.65 (m, 1H), 3.34 (m, 2H), 3.06-2.92 (m, 4H), 2.82 (m, 1H), 2.36 (m, 4H), 1.94 (s, 3H), 
1.31 (s, 6H), 1.17 (m, 3H) ppm; 13C NMR (CD3OD, 150 MHz) δ 205.97, 173.73, 173.43, 
168.18, 155.35, 143.56, 139.07, 132.52, 132.07, 131.85, 131.64, 129.45, 128.01, 127.13, 
126.04, 123.25, 121.72, 113.40, 75.35, 56.59, 56.11, 51.98, 48.24, 44.22, 39.80, 38.81, 
37.79, 30.72, 29.28, 23.70, 23.55, 22.60, 17.51 ppm; HRMS (ESI+) m/z 680.2538 [M + 
Na]+ (C34H44ClN3NaO6S requires 680.2537).    
AcHN
S
O
NHBoc
23  
2-acetamidoethyl-3-(tert-butoxycarbonylamino)propanethioate (23). A 
solution of 3-(tert-butoxycarbonylamino)propanoic acid (20, 250 mg, 1.32 mmol), EDCI 
(506 mg, 2.64 mmol), and DMAP (16 mg, 0.13 mmol) in CH2Cl2 (4 mL)  was prepared 
and allowed to stir at room temperature for 10 minutes. N-acetylcysteamine (169 µL, 
1.59 mmol) was then added and reaction stirred at room temperature for 18 hours. 
Quenched by the addition of saturated aqueous NH4Cl, the organic layer was removed 
and aqueous layer extracted with CH2Cl2 (2 x 10 mL), washed with saturated aqueous 
NaHCO3 (10 mL), brine (10 mL), and water (10 mL). The combined organics were then 
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dried with MgSO4 and solvent removed under vacuum. Flash chromatography (100:0 to 
95:5 CH2Cl2/MeOH) afforded 230 mg of pure thioester 23 as a clear, colorless oil (60%). 
TLC Rf = 0.50 (5% MeOH/CH2Cl2); 1H NMR (CDCl3, 500 MHz) δ 6.15 (bs, 1H), 4.99 
(bs, 1H), 3.41 (q, J = 5.0 Hz, 4H), 3.02 (t, J = 5.0 Hz, 2H), 2.76 (t, J = 5.0 Hz, 2H), 1.96 
(s, 3H), 1.41 (s, 9H) ppm; 13C NMR (CDCl3, 125 MHz) δ 198.61, 170.55, 155.93, 79.69, 
44.45, 36.97, 28.94, 28.48, 23.29 ppm; HRMS (ESI+) m/z 313.1199 [M+Na]+ 
(C12H22N2NaO4S requires 313.1192).  
S
O
NHBoc
24
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(R)-2-acetamidoethyl-3-(tert-butoxycarbonylamino)-2-methylpropanethioate 
(24) and 2-acetamidoethyl-3-(tert-butoxycarbonylamino)-2,2-
dimethylpropanethioate (25) were prepared in an identical manner to thioester 23. 
Compound 24: 82%; TLC Rf = 0.50 (5% MeOH/CH2Cl2); 1H NMR (CDCl3, 500 MHz) δ 
6.17 (s, 1H), 4.95 (s, 1H), 3.37 (m, 4H), 2.98 (m, 2H), 2.90 (m, 1H), 1.96 (s, 3H), 1.41 (s, 
9H), 1.16 (d, J = 5.0 Hz, 3H) ppm; 13C NMR (CDCl3, 125 MHz) δ 202.85, 170.57, 
156.09, 79.68, 49.01, 43.82, 39.10, 28.83, 28.48, 23.29, 15.26 ppm; HRMS (ESI+) m/z 
327.1364 [M + Na]+ (C13H24N2O4S requires 327.1349).  
Compound 25: 78%; TLC Rf = 0.50 (5% MeOH/CH2Cl2); 1H NMR (CDCl3, 500 MHz) δ 
6.18 (s, 1H), 4.91 (s, 1H), 3.40 (q, J = 5.0 Hz, 2H), 3.27 (d, J = 5.0 Hz, 2H), 3.00 (t, J = 
5.0 Hz, 2H), 1.97 (s, 3H), 1.41 (s, 9H), 1.22 (s, 6H) ppm; 13C NMR (CDCl3, 125 MHz) δ 
205.81, 170.51, 156.26, 79.60, 51.24, 49.22, 38.92, 28.69, 28.47, 23.32 ppm; HRMS 
(ESI+) m/z 341.1533 [M + Na]+ (C14H26N2NaO4S requires 341.1505).  
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Boc-3-Cl-D-Tyr(Me)-OH (26). Boc-3-Cl-D-Tyr(Me)-OH was used from a 
preparation for a previous investigation.7  
S
O
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(R)-2-acetamidoethyl-3-((R)-2-(tert-butoxycarbonylamino)-3-(3-chloro-4-
methoxyphenyl)propanamido)-2-methylpropanethioate (27). Thioester 23 (57 mg, 
0.20 mmol) was dissolved in CH2Cl2 (1 mL), charged with trifluoroacetic acid (500 μL), 
and stirred at room temperature for 1 hour. Volatiles removed under vacuum and residue 
dissolved in DMF (1 mL). To this solution was added a solution of Boc-3-Cl-D-Tyr(Me)-
OH (26, 79 mg, 0.24 mmol), PyBOP (203 mg, 0.39 mmol), triethylamine (72 μL, 0.52 
mmol), and DMAP (2 mg, 0.02 mmol). Reaction stirred for 18 hours at room temperature 
and then diluted with CH2Cl2 (5 mL). Organic layer washed with saturated aqueous 
NH4Cl (5 mL), brine (5 mL), and water (5 mL), then dried with Na2SO4. Solvent 
removed under vacuum and residue subjected to flash chromatography (100:0 to 95:5 
CH2Cl2/MeOH) to afford 63 mg of pure compound 27 as a clear, colorless oil (63%). 
TLC Rf = 0.45 (5% MeOH/CH2Cl2); 1H NMR (CD3OD, 500 MHz) δ 7.24 (bs, 1H), 7.12 
(dd, J = 2.2, 8.4 Hz, 1H), 6.97 (d, J = 8.4 Hz, 1H), 4.16 (dd, J = 6.1, 8.8 Hz, 1H), 3.85 (s, 
3H), 3.43 (m, 2H), 3.33 (m, 2H), 3.00 (m, 3H), 2.72 (m, 3H), 1.92 (s, 3H), 1.37 (s, 9H) 
ppm; 13C NMR (CD3OD, 125 MHz) δ 198.44, 174.16, 173.46, 157.55, 155.34, 131.97, 
131.79, 129.90, 123.12, 113.35, 80.68, 57.42, 56.59, 44.09, 40.00, 38.26, 36.51, 29.37, 
28.63, 22.53 ppm; HRMS (ESI+) m/z 524.1585 [M + Na]+ (C22H32ClN3O6S requires 
524.1593).  
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(R)-2-acetamidoethyl 3-((R)-2-(tert-butoxycarbonylamino)-3-(3-chloro-4-
methoxyphenyl)propanamido)-2-methylpropanethioate (28) and (R)-2-
acetamidoethyl 3-(2-(tert-butoxycarbonylamino)-3-(3-chloro-4-
methoxyphenyl)propanamido)-2,2-dimethylpropanethioate (29) were prepared in a 
manner analogous to that used to prepare compound 27. Compound 28: 96%; 1H NMR 
(CD3OD, 500 MHz) δ 7.25 (bs, 1H), 7.13 (dd, J = 2.2, 8.5 Hz, 1H), 6.98 (d, J = 8.4 Hz, 
1H), 4.18 (dd, J = 6.2, 8.6 Hz, 1H), 3.85 (s, 3H), 3.46 (dd, J = 7.0, 13.5 Hz, 1H), 3.33 (m, 
2H), 3.17 (dd, J = 6.5, 13.5 Hz, 1H), 2.98 (m, 3H), 2.84 (q, J = 6.9 Hz, 1H), 2.73 (dd, J = 
8.9, 13.7 Hz, 1H), 1.92 (s, 3H), 1.38 (s, 9H), 1.07 (d, J = 7.0 Hz, 3H) ppm; 13C NMR 
(CD3OD, 125 MHz) δ 202.84, 174.34, 173.46, 157.52, 155.35, 131.95, 131.81, 129.88, 
123.15, 113.37, 80.67, 57.54, 56.60, 43.20, 39.97, 38.27, 29.30, 28.65, 22.56, 15.67 ppm; 
HRMS (ESI+) m/z 538.1748 [M + Na]+ (C23H34ClN3O6S requires 538.1749). 
Compound 29: 89%; 1H NMR (CD3OD, 500 MHz) δ 7.26 (bs, 1H), 7.14 (dd, J = 2.2, 8.4 
Hz, 1H), 6.97 (d, J = 8.4 Hz, 1H), 4.24 (dd, J = 5.9, 9.2 Hz, 1H), 3.85 (s, 3H), 3.33 (m, 
4H), 2.99 (m, 3H), 2.73 (dd, J = 9.3, 13.8 Hz, 1H), 1.93 (s, 3H), 1.37 (s, 9H), 1.19 (s, 
3H), 1.16 (s, 3H) ppm; 13C NMR (CD3OD, 125 MHz) δ 206.00, 174.53, 173.44, 157.56, 
155.33, 131.94, 131.88, 129.86, 123.16, 113.38, 80.66, 57.55, 56.60, 52.03, 48.13, 39.79, 
38.08, 29.30, 28.65, 23.71, 23.56, 22.59 ppm; HRMS (ESI+) m/z 552.1909 [M + Na]+ 
(C24H36ClN3O6S requires 552.1906). 
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Synthesis of cryptophycin unit A (30) 
OH
O
OH
30  
Cryptophycin unit A was synthesized previously according to Eggen et al.8  
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Supplemental Tables and Figures  
# Observed Expected dPPM Start Stop Sequence 
1 1,493.82 1,493.82 1 3 16 TTNSALSLPPIQPR 
2 2,760.52 2,760.48 14 112 136 ESVLHQQAQLAAITPFDLETAPLIR 
3 1,410.72 1,410.70 14 242 254 GTTQSFSLNTDLK 
4 2,227.18 2,227.15 15 263 282 NSGTTLFMTLHAAFATLLYR 
5 2,983.41 2,983.46 -16 335 359 ETTLEAYEHQDVPFEQVVEVLQPQR 
6 2,158.00 2,158.03 -13 432 450 MTAHFQNLCSAIVENPQQK 
7 2,522.25 2,522.26 -4 578 599 IEQALQTAKGVEDCYVMVRNQK 
8 2,784.30 2,784.32 -8 765 789 GITYINSDGSEQVQSYAQLLEDAQR 
9 2,549.28 2,549.28 2 872 892 KWSQNNLNDDNFKLETIESLQK 
10 3,216.50 3,216.46 11 893 921 FSTDKDKDYYNAQPEDLALFMLTSGSTGMSK 
11 1,939.99 1,940.03 -20 1269 1284 SLLKQRFECGEFKSLR 
12 2,034.06 2,034.02 19 1323 1339 TLTLIFTDNLGWQQDNR 
13 2,571.28 2,571.27 2 1384 1404 QNSQVISQILHLWNYNEQTEK 
14 2,399.29 2,399.30 -4 1436 1456 QQAVKLLWIANQSQLVHPTDK 
15 1,862.01 1,862.01 0 1441 1456 LLWIANQSQLVHPTDK 
16 2,205.17 2,205.12 21 1513 1531 NRERFVSGLEPVDMTAKEK 
17 1,392.67 1,392.70 -21 1517 1529 FVSGLEPVDMTAK 
18 2,226.15 2,226.14 4 1625 1644 TQLDGVFHMAGIIQETPIEK 
19 2,354.28 2,354.28 1 1815 1834 FGIPNQINFVQLEQIPLTQR 
20 2,075.06 2,075.07 -1 1840 1858 EQIAAIYGGLNTSEQTKPR 
21 1,725.96 1,725.94 9 1908 1922 KNLPLATLFQNPTIER 
Table S1. CrpD-M2 peptides identified by accurate mass peptide mass fingerprinting 
using direct injection FTICR-MS.  All masses given are monoisotopic and deconvoluted 
in Da. Mass error in ppm, start and stop sites, as well as assigned sequence are all 
provided. 
 
 
# m/z mon z Obsd. Theo. dPPM ID 
1 1,248.3 3 3,741.98 3,741.97 2 Apo + 80 
2 1,215.7 3 3,644.04 3,643.97 19 Apo - 18 
3 1,335.0 3 4,001.94 4,002.06 -29 Holo 3+ 
4 1,001.5 4 4,002.00 4,002.06 -16 Holo 4+ 
5 261.1 1 260.12 260.12 9 Ppt1 
6 359.1 1 358.10 358.10 -8 Ppt2 
7 453.2 1 452.23 452.23 0 b4 - NH3 
8 566.3 1 565.32 565.32 4 b5 - NH3 
9 324.2 1 323.19 323.19 -15 b3 - NH3 
10 1,409.8 1 1,408.78 1,408.76 12 b12 -NH3 
11 788.1 3 2,361.28 2,361.24 18 b14-NH3 
 
Table S2. LC FTICR IRMPD MS2 verification of CrpD-M2 T domain active site. The 
observed monoisotopic molecular weight, charge state, deconvoluted monoisotopic mass, 
and theoretical mass are all provided. Mass errors in ppm and peak identity are also 
provided.  
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A Domain 235 236 239 278 299 301 322 330 331 517 Specificity 
CrpD-M2-A V A I F L G S S G K 2KIC/2HIC 
PksJ-A1 V G W T T A A I C K 2KIC 
BarE-A V G I L V G G   T S K Trichloro-2KIC
BSLS-A1 G A L M V V G   S I K D-2HIV 
BEAS-A1 G A L M I V G   S I K D-2HIV 
CseA-A1 V G V W V G T S G K 2-KIC 
CseB-A1 V G F W V A V S D K 2-KIV 
ENSYN-A1 G A L H V V G I C K D-2HIV 
HctE-A1 V G V W L A L F C K 2KIV 
HctF-A1 V G V W L A L F C K 2KIV 
KtzG-A V T Y F N G P S G K 2-KIV 
Vlm1-A1 A A L W I A V S G K 2-KIV 
Vlm2-A1 V V I W I A E N M K Pyruvate 
BarD D A I L L G G A A K L-Leucine 
Table S3. CrpD-M2 A-domain predicted specificity.  
 
 
 
   Rxn m obs m theo dppm ID Max Int. FTICR-t 
1 L-2HIC  4,116.21 4,116.12 22 2HIC 2.1E+05 82 
2 D-2HIC 4,116.18 4,116.12 15 2HIC 4.3E+05 82 
3 KIC 4,114.15 4,114.12 9 KIC 8.8E+04 81 
4 KIC+NADPH 4,116.14 4,116.12 5 2HIC 1.5E+05 82 
5 KIC+NADH 4,116.20 4,116.12 20 2HIC 7.6E+05 82 
Table S4. CrpD-M2 active site bound intermediates identified by accurate mass using LC 
FTICR-MS. All masses given are monoisotopic, in Da. Mass error is provided in ppm. 
Product identification is provided as ID. Intensity is the average of peak intensity of the 
most abundant charge state averaged over the three most intense scans.  Retention times 
are given in minutes, note that due to instrument configuration (dead-volume, actual 
performance, scan times) LC FTICR and LC LIT–MS retention times differ by 
approximately 8 minutes, although the order of eluted peaks and relative elution time in 
relation to total ion chromatogram is maintained. See Figures S26-30 for associated 
chromatograms and spectra supporting these assignments. 
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 # Rxn 
Parent 
Ion IT-t ID Fragment Ions Identified 
1 L-2HIC  10304+ 74 2HIC 2HIC-Ppt2, Apo - 18 (12163+), Apo + 80 (12493+) 
  13733+ 74  Apo - 18 (18242+), Apo + 80 (18732+) 
  
10304+Æ
12163+ 74  
Apo - 18 MS2 product (12153+) Æ MS3 products: b6, 
b7, b9, b10, b11, b12, b13, y9, y12, y13, y14 
  
13733+Æ
18242+ 74  Apo - 18 MS2 product (18422+) Æ MS3 products: y16 
2 D-2HIC 10304+ 74 2HIC 
2HIC-Ppt1, 2HIC-Ppt2, Apo - 18 (12163+), Apo + 80 
(12493+) 
  13733+ 74  Apo - 18 (18242+), Apo + 80 (18732+) 
  
10304+Æ
12163+ 74  
Apo - 18 MS2 product (12153+) Æ MS3 products: b4, 
b6, b7, b9, b10, b11, b12, b15, b16, y4, y5, y7, y8, y9, y10, y11, 
y12, y13, y14, y15, y16, y17, y18 
  
13733+Æ
18242+ 74  
Apo - 18 MS2 product (18232+) Æ MS3 products: y10, 
y14, y15, y16, y18 
3 KIC 10304+ 74 KIC KIC-Ppt1, Apo - 18 (12163+), Apo + 80 (12493+) 
  13733+ 74   
  
10304+Æ
12163+ 74  
Apo - 18 MS2 product (12153+) Æ MS3 products: b5, 
b6, b7, b9, b10, b11, b12, b13, b14, y3, y4, y5, y7, y8, y9, y11, 
y12, y13, y14, y18 
  
13733+Æ
18242+ 74  
Apo - 18 MS2 product (18232+) Æ MS3 products: b15, 
y9, y14, y15, y16, y18 
4 KIC+NADPH 10304+ 74 2HIC 
2HIC-Ppt1, 2HIC-Ppt2, Apo - 18 (12163+), Apo + 80 
(12493+) 
  13733+ 74  2HIC-Ppt2, Apo - 18 (18242+), Apo + 80 (18732+) 
  
10304+Æ
12163+ 74  
Apo - 18 MS2 product (12153+) Æ MS3 products: b8, 
b9, b10, b11, b12, b13, b15, y3, y7, y9, y10, y11, y13, y14, y16 
  
13733+Æ 
18242+ 74  
Apo - 18 MS2 product (18232+) Æ MS3 products: b15, 
y14, y15, y16 
5 KIC+NADH 10304+ 74 2HIC 2HIC-Ppt1, 2HIC-Ppt2, Apo + 80 (12493+) 
  13733+ 4  Apo - 18 (18242+), Apo + 80 (18732+) 
  
10304+Æ
12163+ 74  
Apo - 18 MS2 product (12153+) Æ MS3 products: b4, 
b5, b6, b9, b10, b11, b12, b13, b15, y4, y6, y8, y9, y10, y11, 
y12, y13, y14, y15, y17, y18 
  
13733+Æ
18242+ 74  
Apo - 18 MS2 product (18232+) Æ MS3 products: b7, 
y9, y11, y14, y16  
Table S5. CrpD-M2 peptides identified by MS2 and MS3 LC LIT-MS.  All masses 
given are average, in Da.  Mass errors of +/- 1 m/z unit were used for peak 
assignment. Only Ppt, apo – 18, and apo + 80 ions are shown for MS2 and only main 
sequence 1+ b and y ions are shown as results from MS3 for clarity. Retention times 
are given in minutes, note that due to instrument configuration (dead-volume, actual 
performance, scan times) LC-FTICR and LC-LIT –MS retention times differ by 
approximately 8 minutes, although the order of eluted peaks and relative elution time 
in relation to total ion chromatogram is maintained. Product identification is provided 
as ID. The Ppt1 ion is the cyclic fragment formed after cleavage at the distal end of the 
phosphate. Ppt2 ion is formed when cleavage occurs at the proximal end of the arm, 
resulting in an ejected ion containing the phosphate. Note that MS2 of the 3+ or 4+ 
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parent predominantly give phosphopantetheine ejection ions, apo - 18, and apo + 18 
charge reduced species.  MS3 fragmentation of the Apo -18 peaks result in a, b and y 
ion series sufficient for peak identification. See Figures 31-35 for further information. 
 
 
Figure S1. Chemical structures of natural cryptophycin analogs. Cryptopycin-1 is 
comprised of four units linked in clockwise order of δ-hydroxyoctenoic acid (unit A), 3-
chloro O-methyl-D-tyrosine (unit B), methyl-β-alanine (unit C), and L-leucic acid (unit 
D). Several cryptophycin analogs carrying variable unit D moieties are also shown. 
 
 
 
Figure S2. 4-12 % SDS-PAGE analysis of N-terminally His-tagged CrpD-M2 after Ni-
NTA resin.  
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Figure S3. CrpD-M2 characterization. (A) Sequence coverage of purified CrpD-M2 by 
amino acid number, as determined by direct inject FTICR-MS peptide fingerprint 
mapping. (B) Identification of CrpD-M2 T domain active site with LC FTICR-MS as m/z 
versus absolute intensity. The deconvoluted 4+ ion at a monoisotopic mass of 1,001.51 
m/z with has an observed molecular weight of 4,002.00 Da as compared to an expected 
molecular weight of 4,002.06 Da. 
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A. 
 
B. 
Region 88-103 Region 134-149 
HMAGIIQETPIEKETP...FCSVNGFFGGTNVAAY CrpDm2_KR Æ ?-type 
HLAGIIQEILIEKQTE...TSSARTLLPGMTISAY CesA_KR   Æ ?-type 
HLAGAGNLEEHWSEID...FSSVNSYFGGASFTAY CesB_KR   Æ ?-type 
EDAGYAARQIPQTSVF... CSSSLIGLHSAYKSLY PksJ_KR  Æ ?-type     
HAAATLDDGTVDTLTG...FSSFASAFGAPGLGGY DEBSKR1   Æ B-type  
HTAGALDDGIVDTLTA...FSSVSSTLGIPGQGNY PikKR1   Æ B-type  
HAAGLPQQVAINDMDE...FSSGAGVWGSARQGAY DEBSKR2   Æ A-type   
HAAGVSTSTPLDDLTE...FSSNAGVWGSPGLASY DEBSKR5   Æ A-type   
HTAGVPESRPLHEIGE...FSSGAGVWGSANLGAY DEBSKR6   Æ A-type   
 
Figure S4. (A) Phylogenetic analysis of CrpD-M2 KR domain.  CrpD-M2 KR domain 
was grouped with other NRPS KR domains, which grouped into a distinct category 
compared to type I module PKS and type II discrete PKS β-KR domains. The tree was 
constructed using the Neighbor-Joining method and was drawn to scale, with branch 
lengths in the same units as those of the evolutionary distances used to infer the 
phylogenetic tree. The scale bar indicates the number of amino acid substitutions per site.  
Alignment of sequences and the phylogenetic tree were constructed using MEGA 4.0.9 
(B) Multiple alignments showing specificity determining regions for PKS β-KR domains. 
Based on sequence analysis of multiple biosynthetic pathways and product analysis, 
guidelines were established for determining PKS-KR domain stereospecificity.10 This 
findings were later verified with in vitro biochemistry for a series of free PKS enzyme 
domains with model substrates.11 When this analysis is applied to CrpD-M2, we can 
determine that it is neither an A-type nor B-type PKS KR based upon its inability to meet 
the criteria for either. For example in region 88-103 CrpD-M2 KR does not contain the 
LDD motif typical of group B, with a strictly conserved L93, D94 or E94 and an 
invariant D95. In region 134-149 it does not contain the B-group P144 and N148, nor 
does it contain the A-group W141. Thus this NRPS KR domain appears to fall into a 
separate KR class based upon primary amino acid sequence as well as analysis of known 
product structures (Figure S5). 
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Figure S5. Known ketoreductase catalyzed reactions for T-domain bound substrates in 
NRP natural products. 
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Figure S6. LC FTICR-MS2 spectra of cryptophycins. Data are presented as m/z versus 
absolute signal. (A) cryptophycin 3 CID MS2 fragmentation spectra. (B) cryptophycin 51 
CID MS2 fragmentation spectra. Assigned ions are denoted in blue. Key ions are noted in 
red, with the mass shift in green. Mass errors and observed MH+ values are also provided. 
All assigned peaks were within 15 ppm of the theoretical value. All unit B containing 
peaks had the predicted 37Cl +2 isotope profile. 
 
 
 
Figure S7. Crp 3 HPLC co-elution analysis with authentic standard. (A) A negative 
control reaction (ATP, L-2HIC extender unit, SNAC-ABC chain elongation intermediate 
(3-amino-2(R)-methylpropionyl, 3), and boiled enzymes (CrpD-M2 and Crp TE). (B) A 
full reaction (ATP, L-2HIC extender unit, SNAC-ABC chain elongation intermediate (3-
amino-2(R)-methylpropionyl, 3), CrpD-M2, and Crp TE). (C) Authentic standard of 
cryptophycin 3.   
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Figure S26. LC-FTICR MS total ion chromatograms for CrpD-M2 samples reacted with 
ATP and compounds as noted above (A-E). Data are presented as normalized intensity 
versus time, with the elution window for the identified species noted (*). 
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Figure S27. LC-FTICR MS extracted ion chromatograms for CrpD-M2 samples reacted 
with ATP and compounds as noted above with extracted m/z value and tolerance 
displayed (A-E). The targeted ions in the 4+ charge state as presented in Figure 3 are 
illustrated. Other peaks at a similar m/z value were manually inspected and found to not 
match the targeted peptide (e.g. incorrect charge, mass value is not the monoisotopic 
peak, present in negative control reaction, not confirmed by MS2 and MS3). Data are 
presented as normalized intensity versus time, with the elution window for the identified 
species noted (*). The signal intensity in Figure S27 C is lower as compared to other 
species, although present (Figure S28-S29 C).  
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Figure S28. CrpD-M2 T domain active-site bound with extender unit intermediates 
monitored by LC FTICR-MS. A zoomed mass spectrum averaged over the elution 
window is presented. The deconvoluted monoisotopic mass, and observed charge state 
are shown. Reactions of CrpD-M2 with ATP and: (A) L-2HIC (2), (B) D-2HIC (20), (C) 
2KIC (1), (D) 2KIC  +NADPH, (E) 2KIC +NADH. Further data  are provided such as 
LC IT-MS/MS4 (Table S4-5).  
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Figure S29. LC-FTICR MS full spectra averaged over the elution window for CrpD-M2 
rections (A-E). Data are presented as absolute intensity versus m/z values. The 4+, and 3+ 
charge states can be observed for all samples, indicating that indicating that the signals 
are real and greater than the noise. 
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Figure S30. LC-FTICR MS intermediate zoomed spectra averaged over the elution 
window for CrpD-M2 rections (A-E) in the 4+ charge state. Data are presented as 
absolute intensity versus m/z values. This data illustrates that the identified peaks are 
greater than the noise, as well as the fine isotopic splitting of the ions. 
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Figure S31. LC-IT MS2 and MS3 data for CrpDm2, ATP, and L-2HIC. Extracted ion 
chromatograms are presented for the 4+ loaded active site peptide (A) and the 3+ loaded 
active site loaded peptide (C) as well as the 4+ apo – 18 active site peptide (E) and the 3+ 
apo – 18 active site loaded peptide (G) as time versus normalized intensity. Assigned 
MS2 (B, D) and MS3 (F, H) spectra are shown as m/z values versus absolute intensity. 
 
 
Figure S32. LC-IT MS2 and MS3 data for CrpDm2, ATP, and D-2HIC. Extracted ion 
chromatograms are presented for the 4+ loaded active site peptide (A) and the 3+ loaded 
active site loaded peptide (C) as well as the 4+ apo – 18 active site peptide (E) and the 3+ 
apo – 18 active site loaded peptide (G) as time versus normalized intensity. Assigned 
MS2 (B, D) and MS3 (F, H) spectra are shown as m/z values versus absolute intensity. 
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Figure S33. LC-IT MS2 and MS3 data for CrpDm2, ATP, and 2KIC. Extracted ion 
chromatograms are presented for the 4+ loaded active site peptide (A) and the 3+ loaded 
active site loaded peptide (C) as well as the 4+ apo – 18 active site peptide (E) and the 3+ 
apo – 18 active site loaded peptide (G) as time versus normalized intensity. Assigned 
MS2 (B, D) and MS3 (F, H) spectra are shown as m/z values versus absolute intensity. 
 
 
Figure S34. LC-IT MS2 and MS3 data for CrpDm2, ATP, and 2KIC +NADPH. 
Extracted ion chromatograms are presented for the 4+ loaded active site peptide (A) and 
the 3+ loaded active site loaded peptide (C) as well as the 4+ apo – 18 active site peptide 
(E) and the 3+ apo – 18 active site loaded peptide (G) as time versus normalized 
intensity. Assigned MS2 (B, D) and MS3 (F, H) spectra are shown as m/z values versus 
absolute intensity. 
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Figure S35. LC-IT MS2 and MS3 data for CrpDm2, ATP, and and 2KIC +NADH. 
Extracted ion chromatograms are presented for the 4+ loaded active site peptide (A) and 
the 3+ loaded active site loaded peptide (C) as well as the 4+ apo – 18 active site peptide 
(E) and the 3+ apo – 18 active site loaded peptide (G) as time versus normalized 
intensity. Assigned MS2 (B, D) and MS3 (F, H) spectra are shown as m/z values versus 
absolute intensity. 
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